Hikma Pharma shares rise on 'unsolicited enquiries'
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."
The share price rose 4.85% to 908p by 12:05.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
NR
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Regulator moves to protect access to cash amid branch closures and disappearing ATMs
News The Financial Conduct Authority has told banks to start assessing if local communities have adequate cash access from mid-September
By Marc Shoffman Published
-
VAT hike on private school fees could come earlier than previously expected
The government could start charging VAT on private school fees as soon as January 2025, according to the latest reports. What does it mean for parents?
By Katie Williams Published